Welcome, Guest. Please login or register.
January 26, 2021, 11:36:45 am

Login with username, password and session length

  • Total Members: 35709
  • Latest: Bobbis
  • Total Posts: 758138
  • Total Topics: 64196
  • Online Today: 263
  • Online Ever: 4912
  • (November 13, 2019, 02:56:14 am)
Users Online
Users: 4
Guests: 236
Total: 240


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Starting HIV Treatment Very Early Offers Strong Benefits  (Read 767 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 16,592
  • Twitter @JimAllenDublin
    • HIV Lessons
Starting HIV Treatment Very Early Offers Strong Benefits
« on: July 16, 2019, 04:45:21 pm »
More reason to adapt test & treat model, although at least looking at my own nation with the testing capacity issues it would undermine early treatment *

Full writeup

In short

Publishing their findings in the journal AIDS, Shweta Sharma, MBBS, of the School of Public Health at the University of Minnesota, and colleagues with the INSIGHT START Study Group conducted an analysis of data from the randomized, controlled START study, the main findings of which were first reported in 2015.

A total of 373 participants were considered recently infected and thus in what the investigators called Group 1. These individuals reported contracting HIV within six months of enrolling in START or were diagnosed with the virus during that same period and tests of their HIV antibodies indicated a recent infection.

Meanwhile, 2,634 people had contracted HIV six to 24 months prior to enrolling in START and were in Group 2. Group 3 consisted of 1,605 people who had been living with the virus for two or more years.

At the study’s outset, the median CD4 count was 660 in Group 1, 654 in Group 2 and 644 in Group 3. The CD8 counts of those in Group 1 were also lower than those of the members of Group 2 or 3, suggesting that their immune function had a greater level of abnormality at the beginning of the study.

Compared with those in the other two groups, individuals in Group 1 were more likely to have an initial viral load above 50,000 and less likely to have a viral load below 3,000.

During an average follow-up of three years, the average overall rise in CD4 count was 194, including an increase of 231 cells in those in Group 1, 202 cells in those in Group 2 and 171 cells in those in Group 3. The members of Group 1 also saw their CD4 to CD8 ratio increase, suggesting they experienced a greater normalization of their immune function.

Among those in the deferred-treatment arm of the study, those in Group 1 were 52% more likely to see their CD4s decline to less than 350 or to receive an AIDS diagnosis compared with those in Group 3. For each 100 cumulative years of study follow-up, those in Group 1 experienced a median of 15.6 cases of HIV disease progression while those in Group 3 experienced 10.5 cases.

« Last Edit: July 16, 2019, 04:54:39 pm by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.